Načítá se...
Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors (TKIs) such as imatinib. Most patients are maintained in a disease-suppressed state on daily TKI therapy for several...
Uloženo v:
| Vydáno v: | Mol Cell Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4904890/ https://ncbi.nlm.nih.gov/pubmed/27308345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/23723548.2014.963450 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|